Boehringer Ingelheim reports positive results from two global Phase III trials of its glucagon/GLP-1 dual agonist survodutide.

Zealand Pharma (ZLDPF) announced that Boehringer Ingelheim has reported positive results from two global Phase III trials of its glucagon/GLP-1 dual agonist survodutide, Synchronize-1 and Synchronize-MASLD. Key highlights: News builds on previously announced positive topline results from Synchronize-1 76-week trial, which met its primary endpoints and showed up to 16.6% weight loss with survodutide, a novel glucagon/GLP-1 dual agonist, from baseline. Detailed pre-specified analysis from a sub study of Synchronize-1 show that, relative to baseline, survodutide achieved a reduction of up to 34% in visceral fat, with the proportion of lean mass loss reflecting no more than 10.8% of change in total tissue mass at the highest dose, alongside an up to 63.1% reduction of liver fat, indicating a targeted reduction in metabolically harmful fat after 76 weeks. Detailed results presented from Synchronize-MASLD, showed that the trial met both its primary endpoints, with additional results showing that, relative to baseline, liver fat normalization was reached by 6 out of 10 participants living with metabolic dysfunction-associated steatotic liver disease and obesity or overweight who were treated with survodutide after 48 weeks. The Synchronize-1 and Synchronize-MASLD results were presented at the American Diabetes Association’s 2026 Scientific Sessions and simultaneously published in The New England Journal of Medicine and Nature Medicine, respectively Claim 55% Off TipRanks

Meningioma is the most common brain tumor in adults.

Scientists who study the Y chromosome expect to find a record of loss.

A 10-year study in sub-Saharan Africa revealed that a higher dose of the oral medication Hydroxyurea improved survival and growth outcomes in children with sickle cell anemia.